New US approval for Takeda’s Alunbrig
The move is based on data showing Alunbrig’s superiority over crizotinib as first-line treatment of metastatic ALK+ NSCLC
Read More
Tag: brigatinib
Expanded EU approval for Takeda’s Alunbrig
The expanded indication provides the around 10,000 people living with ALK+ NSCLC in Europe an additional first-line treatment option
Read More
Preliminary NICE ‘no’ for Takeda’s Alunbrig
Draft guidelines from the National Institute for Health and Care Excellence do not recommend NHS funding for Takeda’s lung cancer drug Alunbrig.
Read More
Takeda’s Alunbrig shows promise as first-line ALK NSCLC therapy
Takeda’s Alunbrig cut the risk of disease progression or death by more than 50% compared to Pfizer’s Xalkori in adults with ALK+ non-small cell lung cancer.
Read More
CHMP puts 13 therapies forward for EU approval
Marking a bumper month for Committee for Medicinal Products for Human Use (CHMP) decisions, 13 medicines have been put forward for approval in the region, including three orphan medicines.
Read More
Takeda’s Alunbrig beats Pfizer’s Xalkori on PFS in ALK positive NSCLC
Takeda’s Alunbrig has beaten Pfizer’s Xalkori on progression-free survival (PFS) in a Phase III trial testing its efficacy as a front-line treatment for ALK-positive lung cancer.
Read More
Takeda’s lung cancer drug approved in the US
Takeda Pharmaceuticals has bagged approval for Alunbrig in the US as a treatment for a specific group of lung cancer patients.
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
